Hyperlipidemia is a comorbidity affecting a significant number of transplant patients despite treatment with cholesterol lowering drugs. Recently, it has been shown that hyperlipidemia can significantly alter T-cell responses to cardiac allografts in mice, and graft rejection is accelerated in dyslipidemic mice. Here, we review recent advances in our understanding of hyperlipidemia in graft rejection.
INTRODUCTION
Organ transplantation is currently the only treatment for end-stage organ failure, and development of modern immunosuppressive drugs has resulted in impressive 1-year survival rates [1] . However, elucidating immune and nonimmune factors that affect long-term organ survival remains some of the most challenging and complex areas of medicine. Indeed, despite the improvements in short-term survival, long-term survival rates have not changed over the last 20 years, and late graft rejection remains a major cause of mortality in patients more than 1 year after transplantation [1] .
The field of transplantation immunology has traditionally relied on the use of inbred animal models to study rejection. However, it is important to recognize that the majority, if not all, of animal models fall short in their ability to model clinical transplantation conditions. For example, standard mouse transplant models do not take into consideration effects on donor organs of brain death or prolonged ischemic time as a result of transplant harvest, factors that can significantly impact rejection and organ survival [2, 3] . Nor do standard transplant models address preexisting or concomitant health conditions present in the human transplant population that might affect outcomes. Indeed, transplant patients typically suffer from preexisting health conditions that either result from or lead to systemic inflammation such as diabetes, obesity and atherosclerosis [4] . Increased inflammation in the recipient could significantly impact responses to alloantigen, modify mechanisms of rejection and negatively impact long-term survival of the transplanted organ. Consideration of these comorbidities in terms of how they affect rejection and acceptance has not been studied in depth until recently. Analyzing transplant rejection and tolerance induction in the context of concomitant health conditions prevalent in the human transplant population has revealed that our canonical understanding of rejection and tolerance may have to be revised to incorporate the influence of comorbidities that affect outcomes in transplantation.
EFFECTS OF HYPERLIPIDEMIA ON GRAFT REJECTION IN HUMANS
One example of a preexisting or concomitant condition that might affect transplant outcome is hyperlipidemia, a condition affecting a majority of transplant patients [5, 6] . Hyperlipidemia is an increased level of lipids in the blood including increased cholesterol and triglycerides. Increases in serum cholesterol levels, especially the lowdensity lipoprotein (LDL) fraction, correlate with the development of atherosclerosis [7] . Atherosclerotic coronary artery disease resulting in ischemic cardiomyopathy is the cause of end-stage heart disease in approximately 40% of all patients requiring a heart transplant [8] . Atherosclerosis resulting from high cholesterol pretransplant or posttransplant is well understood to be a chronic inflammatory disease [9] [10] [11] [12] [13] [14] [15] [16] [17] . Humans with atherosclerosis exhibit increased serum cytokine levels, in particular inflammatory cytokines such as IL-6, IL-17, IL-18, IL-23, IL-27 and interferon-g. High levels of cholesterol and triglycerides also develop in 50% of heart transplant patients after the first year of transplant, and as high as 95% of patients within 5 years. (www.nhlbi.nih.gov). In spite of treatment, twothirds of transplant patients remain dyslipidemic and a significant number of heart transplant patients are statin intolerant [18, 19] . The net result is that the majority of transplant patients experience a significant length of time with elevated lipid levels, and therefore any alteration in antidonor responses will be highly relevant in a clinical setting.
One clue suggesting that hyperlipidemia affects transplant survival can be found in chronic rejection of cardiac transplants. Chronic rejection manifests itself as cardiac allograft vasculopathy (CAV), characterized by obliterative vasculopathy, infiltration of leukocytes, luminal occlusion and fibrosis [20] . CAV affects approximately 8, 30 and 50% of patients who survive 1, 5, and 10 years posttransplant, respectively [1] . Survival after development of CAV is significantly lower compared with patients who do not develop CAV [1] . Graft failure from CAV accounts for 30-50% of deaths of heart transplant patients after 1 year [20, 21] . A major recipient characteristic associated with cardiac allograft rejection after the first year is a history of ischemic heart disease resulting from coronary artery disease caused by hyperlipidemia [8] . Several studies have found a direct correlation between dyslipidemia and development of late graft rejection. Increases in the ratio of triglycerides to high density lipoprotein (HDL) are correlated with increased frequency and severity of CAV [22] . Similarly, preexistent dyslipidemia at the time of heart transplant has been found to be a significant risk factor for the development of CAV [23] . Progression of CAV monitored using three-dimensional intravascular ultrasound correlates with increases in total cholesterol and LDL [24] . And total cholesterol levels after 1 year appear to have prognostic value in determining which patients will develop CAV [25] . Thus, there is a significant body of evidence suggesting that hyperlipidemia in human transplant patients has effects on allograft survival.
Although hyperlipidemia can promote CAV, reducing lipids can reduce incidences of rejection. Indeed, the standard treatment for hyperlipidemia is administration of cholesterol-lowering statins [26] . Statins decrease the incidence of acute rejection, improve 1-year survival and reduce the development of CAV [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] . Although these effects may be related to their ability to lower lipid levels, statins also have immunomodulatory properties that are independent of lipid lowering [44] [45] [46] . Indeed, statins have immunomodulatory properties in monocytes [34] [35] [36] [37] [38] [39] [40] [41] [42] and T cells [36, 37, 47, 48] . Nevertheless, although the mechanisms by which statins improve transplant outcome are unclear, it is reasonable to suggest that lipid lowering protects against the effects of hyperlipidemia on transplant survival. However, it is important to point out that because of problems with statin usage, two-thirds of transplant patients remain dyslipidemic and many transplant patients are statin intolerant [18, 19] . This raises the clinically relevant issue of whether more aggressive statin therapy, or new approaches to control hyperlipidemia may improve outcomes.
MODELING EFFECTS OF HYPERLIPIDEMIA ON TRANSPLANT SURVIVAL IN MICE
Most mouse strains commonly used in transplantation studies, such as C57BL/6 mice, have low plasma lipid levels, including low levels of LDL, and do not naturally develop atherosclerosis. When fed a high-fat diet meant to mimic the typical western diet, C57BL/6 mice experience increased blood lipid levels and development of atherosclerotic lesions [49, 50] . However, even in mice fed a highfat diet, plasma lipid levels of LDL and very low LDL (VLDL) never approach levels observed in humans. Several models of altered plasma lipids have been developed for the study of atherosclerosis, including apolipoprotein E (ApoE)-deficient mice [51] . ApoE together with apolipoprotein B is the major protein constituent of LDL and VLDL. ApoE mediates the uptake of VLDL particles through the LDL and LDL receptor-related protein pathways. Deletion of ApoE therefore results in a large increase in the plasma levels of LDL and VLDL because of the failure to clear lipoproteins from plasma. Ratios of plasma cholesterol, LDL, VLDL, HDL and triglycerides are more similar to that seen in hyperlipidemic humans [10, [51] [52] [53] . Feeding ApoE -/-mice a high-fat diet leads to a further increase in serum cholesterol [51-53,54 && ]. And, unlike wild-type mice fed a high-fat diet, ApoEdeficient mice do not become obese or hyperglycemic, allowing the study of the effects of high plasma lipid levels without these confounding comorbidities which have been shown to have independent effects on immunity [55, 56] .
Several studies have indicated that hyperlipidemic ApoE -/-mice have systemic immune system changes, similar to those seen in hyperlipidemic patients. ApoE knockout mice have increased T-helper type 1 (Th1) and Th17 responses [15] [16] [17] and show changes in response to pathogens [57] [58] [59] . Thus, ApoE -/-mice display immunological changes typical of those seen in humans with atherosclerosis secondary to hyperlipidemia. We therefore used ApoE-deficient mice as a model to study the effects of hyperlipidemia on transplant rejection [54 && ,60] . To examine the effects of hyperlipidemia on graft survival, we examined survival of allogeneic hearts heterotopically transplanted into hyperlipidemic recipients. Fully allogeneic heart grafts are rapidly rejected when transplanted into normal recipients. Indeed, BALB/c hearts transplanted into control C57BL/6 recipients were rejected with a median survival time (MST) of 8 days. Transplantation of BALB/c hearts into hyperlipidemic recipients resulted in rejection with an MST of 6 days. These data provided the first indication that hyperlipidemia promotes rejection. However, while this was a significant difference, the rapid rejection response made it difficult to study changes in rejection kinetics. We therefore took advantage of a murine model of chronic rejection to study how hyperlipidemia alters transplant rejection in which major histocompatibility complex (MHC) class II disparate C57BL/6.C-H2 bm12 hearts (bm12) are transplanted into C57BL/6 mice. Bm12 hearts transplanted into control C57BL/6 mice fed normal chow survived long term as expected (>100 days) but displayed signs of chronic allograft vasculopathy by day 60 when examined by histology as reported previously [61] . In contrast, bm12 hearts transplanted into ApoE -/-mice fed a high-fat diet were acutely rejected and stopped beating with an MST of 21.5 days. Acute rejection in hyperlipidemic hosts resulted from alloreactivity, as syngeneic grafts survived long term (>100 days). This startling change in the kinetics of rejection was not because of the immunomodulatory effects reported for ApoE [54 && ]. ApoE -/-mice fed normal chow rejected bm12 heart grafts more slowly than ApoE -/-mice fed a high-fat diet that have much higher blood lipid levels because of diet [55] . Thus, rejection appeared to correlate with the degree of hyperlipidemia rather than ApoE status. We further examined whether inducing hyperlipidemia in wild-type mice would affect graft rejection. C57BL/6 mice fed a high-fat diet were hyperlipidemic after 4 weeks, and exhibited accelerated rejection of transplanted H-2 K bm12 hearts. Thus, rejection of heart grafts is accelerated independently of obesity, hyperglycemia, high-fat diet and ApoE -/-mutation status, but is correlated with degree of hyperlipidemia. Accelerated rejection of cardiac grafts in mice on a high-fat diet has recently been confirmed by a study performed comparing mice on a high-fat diet with mice given a lowfat diet [62 & ]. Together, these data point to a role for hyperlipidemia in transplant rejection.
MECHANISMS OF REJECTION IN HYPERLIPIDEMIA
Th1 cells [63] [64] [65] are considered the main CD4 T-cell subset that mediates rejection [66] [67] [68] [69] . Th17 cells represent a unique CD4 T-cell lineage derived from naive T cells stimulated in the presence of transforming growth factor beta and IL-6 or IL-21 [70] [71] [72] [73] [74] [75] [76] [77] [78] [79] [80] [81] [82] [83] [84] . We and others have suggested that Th17 cells may be involved in transplant rejection, however, their role is controversial because the majority of studies implicating Th17 cells in rejection have relied on models with questionable physiological relevance such as T-bet-deficient mice [85] [86] [87] [88] [89] [90] [91] [92] [93] [94] [95] [96] [97] [98] [99] . In hyperlipidemic mice that rapidly rejected transplanted bm12 hearts, we observed an increased frequency of T cells producing IL-17 in the periphery. We also observed that a significant number of graft infiltrating cells observed in bm12 as well as fully allogeneic BALB/c hearts transplanted into hyperlipidemic recipients produced IL-17. Interestingly, IL-17 producing graft infiltrating cells were not observed in hearts undergoing rejection in control recipients. Mechanistically, IL-17 production contributed to rejection as survival of bm12 hearts was significantly prolonged when IL-17 was neutralized, or genetically deleted. These data suggest that the condition of hyperlipidemia promotes a rejection response that involves a TH17 component not observed in mice with normal lipid levels.
CHOLESTEROL IN T-CELL ACTIVATION
It is well established that T-cell activation and clonal expansion require significant synthesis of cholesterol containing membranes [100] . T cells accumulate cholesterol either through cellular synthesis or through the uptake of exogenous cholesterol via low-density lipoprotein receptor (LDLR) or alternate receptors [100] . [101] . SREBP-deficient CD8 T cells display defective proliferation and deficient clonal expansion during viral infection [102] . Pharmacological inhibition of acetyl-CoA acetyltransferase, a key cholesterol esterification enzyme, leads to increased CD8 T-cell cytotoxicity, TCR clustering and TCR signaling [103 && ]. In addition to the effects of cholesterol on T-cell proliferation, mounting evidence suggests that cholesterol is involved in TCR-mediated signal transduction. Cholesterol binds to the TCR-b chain [104] , and the ratio of cholesterol to inhibitory cholesterol derivatives can potentiate TCR receptormediated activation [105] .
Cholesterol has also been shown to play a role in T-cell polarization following activation. Although oxysterol-induced LXR prevents Th-17 T-cell generation through inhibiting aryl hydrocarbon receptor-dependent IL-17 transcription [106] , several non-LXR agonist oxysterols induce retinoic acid-related orphan receptor gt, the master transcriptional element controlling Th-17 development [107] . Exogenous supplementation of cultures with these oxysterols results in preferential development of Th-17 cells [107] . In addition, regulatory T cells appear to be particularly sensitive to cholesterol for proper function. Inhibition of 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase, which controls cholesterol synthesis, prevents Treg proliferation and impairs Treg function [108] . Similarly, specific deletion of ABCG1 increases Treg proliferation [109] . In the LDL receptor knockout model of hyperlipidemia, increases in the splenic frequency of regulatory T cells were correlated with changes in phenotype, and their functional inability to control atherosclerotic lesion [110] .
Although lipids such as cholesterol play a role in T-cell activation as discussed above, in order to be applicable to patients with hyperlipidemia, it would have to be shown that disruptions in normal cholesterol homeostasis in T cells can be caused by excessive concentrations of exogenous lipid in the plasma. Although the connection has not yet been proven, there are several lines of evidence suggesting that in addition to the endogenous pathways of cholesterol control, the uptake of exogenous cholesterol also plays a critical role in T-cell-mediated immunity. Blocking cholesterol uptake by culturing cells in media depleted of LDL or genetic deletion of LDL receptors reduces T-cell proliferation [111, 112] , suggesting that lipids must be present in the culture media to facilitate optimal T-cell activation. Also, evidence exists that genetic deficiencies in the cholesterol synthesis pathway can be partially rescued by the presence of exogenous cholesterol. Exogenous cholesterol supplementation of T cells deficient in the SREBP can restore both clonal expansion and effector cytokine production, in T cells [102] . In-vivo administration of squalene, a precursor of cholesterol, to mice also increases membrane cholesterol in CD4 T cells, and promotes raft localization of cytokine receptors [113] . Given these data, it appears likely that many of the immunological alterations observed in hyperlipidemic mice may be due to effects of altered cholesterol levels on T-cell function. It is therefore of major importance to determine whether these functional changes were reversible when lipid levels are reduced. In at least one study, it has been reported that the effects of hyperlipidemia on T-cell function are indeed reversible. In ApoE -/-mice in which lipid levels were lowered through dietary intervention, it was found that T-cell production of IL-10 and IL-12 was decreased in a manner that correlated with cholesterol levels [111] .
EFFECTS OF CHOLESTEROL ON ANTIGEN-PRESENTING CELLS
As is observed in T cells, cholesterol plays an important role in the maintenance of membrane fluidity essential for proper antigen-presenting cell (APC) function [114, 115] Abcg1 À/À macrophages, which have impaired cholesterol efflux and elevated cholesterol levels, exhibit an intrinsic bias toward 'M1' polarization with increased nuclear factor kappa-light-chain-enhancer of activated B cells activation [116] . Furthermore, Abcg1
À/À macrophages have been shown to display enhanced proinflammatory cytokine production [117, 118] . OxLDL induces autophagosome formation, MHC-II expression and phosphorylation of spleen tyrosine kinase in macrophages [119] . Several studies have suggested a role for cholesterol in the development and maturation of dendritic cells. Oxidized cholesterol can promote the differentiation of monocytic precursors into phenotypically mature dendritic cells [120] . Treatment of dendritic cells in vitro with ox-LDL correlated with the upregulation of the costimulatory molecules CD86 and MHC-II and the downregulation of the coinhibitory molecule programmed death ligand-1 [121] . Thus, alterations in cholesterol transport and metabolism have intrinsic effects on antigen presentation.
However, when antigen presentation is studied in vivo, results have been contradictory. When dendritic cell subsets are isolated from hyperlipidemic ApoE -/-mice, they do not have altered antigen presenting function [122, 123] . It has been suggested that ApoE -/-macrophages are more activated [124, 125] and have reduced scavenging capacity [126] . In a model of high-fat diet-induced obesity, hyperglycemia and hyperlipidemia, increased percentages of CD11c high dendritic cells, CD11c
plasmacytoid dendritic cell were found in the spleen; however, these cells had decreased stimulatory capacity [127] . Similarly, in a recent study, dendritic cells isolated from C57BL/6 mice fed a high-fat diet for 8 weeks showed no changes in their ability to stimulate CD4 þ CD25 À effector cells in vitro [128] . Thus, overall antigen presentation in hyperlipidemic mice remains unchanged, or slightly impaired. These results differ from a recent study in which APCs derived from mice fed high-fat diet were suggested to have greater stimulatory capacity because of upregulation of costimulatory molecules [62 & ]. However, in this study, control mice were fed a low-fat diet, rather than normal chow, possibly decreasing the stimulatory capacity of APC from these control mice.
HYPERLIPIDEMIA AND REGULATORY T CELLS
We found a significant expansion of CD4 
CD25
-cells were measured. We also observed that Tregs derived from hyperlipidemic animals were less suppressive in vitro than Tregs from C57BL/6 mice fed normal chow. Interestingly, previous studies have also suggested that incubation with OxLDL can significantly reduce the suppressive properties of CD4 þ CD25 þ Foxp3 þ T cells [130] . T cells from hyperlipidemic mice also expressed significantly lower levels of the proapoptotic molecule Bim, which has previously been implicated in Treg function [131] . Given the importance of Tregs in tolerance induction, we reasoned that alterations in Tregs in hyperlipidemic mice might affect the ability to induce tolerance using approaches that require Tregs, such as costimulatory molecule blockade [132] [133] [134] [135] [136] . Indeed, costimulatory molecule blockade using cytotoxic T lymphocyte-associated protein 4-immunoglobulin fusion protein and anti-CD154 failed to induce tolerance to fully allogeneic cardiac transplants in hyperlipidemic mice. Insofar as the majority of transplant patients become hyperlipidemic, we hypothesize that hyperlipidemia represents a barrier to costimulatory molecule blockade-induced tolerance in patients.
CONCLUSION
The data suggest that hyperlipidemia profoundly changes the host's immune response to donor antigens, the ability to regulate immune responses and establish immunological tolerance. These studies indicate the importance examining whether similar changes are observed in humans with hyperlipidemia. Furthermore, it raises the important question of whether our inability to improve mortality rates beyond the first year of heart transplantation in the last two decades may be related to a failure to consider how concomitant health conditions affect the transplant population. Conditions such as hyperlipidemia, obesity and hyperglycemia are both prevalent in the human transplant patient and are known to be proinflammatory. These conditions may therefore affect responses to donor antigen and their regulation. If hyperlipidemia leads to similar alterations in humans, it may be possible to improve transplant outcomes by targeting T-cell subsets that contribute to rejection in hyperlipidemic hosts, or by developing therapies that allow for maintenance of full Treg function. Indeed, it is possible that the inability to induce tolerance or long-term allograft survival in humans using costimulatory molecule blockade may be due at least in part to the effects of hyperlipidemia on antidonor responses and the ability to regulate them. Although the effects of hyperlipidemia on immune status in humans are poorly understood, it is becoming clear that hyperlipidemia can promote IL-17 responses and inflammation [10,54 && ,137] . Improving control of hyperlipidemia, or developing new approaches that target novel effectors and promote regulation may allow for the establishment of transplant tolerance.
